Product Description
Alalevonadifloxacin (WCK 2349) is a novel l-alanine ester prodrug of levonadifloxacin that is being developed as an oral fluoroquinolone antibiotic. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29263070/)
Mechanisms of Action: DNA Replication Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dr. Reddy's Laboratories
Company Location: Asia Pacific
Company Founding Year: 1984
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02217930 |
W-2349-101 | P1 |
Completed |
Other |
2014-12-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT02253342 |
W-2349-103 | P1 |
Completed |
Healthy Volunteers |
2014-12-01 |
2019-03-20 |
Treatments |
|
NCT02244827 |
W-2349-102 | P1 |
Completed |
Healthy Volunteers |
2014-12-01 |
2019-03-20 |
||
NCT01875939 |
W 771/2349-101 | P1 |
Completed |
Healthy Volunteers |
2013-06-01 |
2019-03-19 |
Treatments |
|
NCT04874324 |
WCK 2349/ P-I/ MD/ 08 | P1 |
Completed |
Healthy Volunteers |
2011-05-04 |
2021-05-06 |
Primary Endpoints |